Vanden Eynde Jean Jacques
Formerly Head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.
Pharmaceuticals (Basel). 2021 Jul 11;14(7):664. doi: 10.3390/ph14070664.
The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon β-1a; remdesivir. The trial was discontinued due to the lack of positive results. Meanwhile, many other potential options have been considered either to target the virus itself, the interactions with the host cells, or the cytokine storm frequently observed during the infection. Several of those options are briefly reviewed. They include vaccines, small molecules, antibodies, and stem cells.
DISCoVeRy临床试验旨在评估针对重症至危重症COVID-19患者的四种治疗方法：羟氯喹，最终联合阿奇霉素；洛匹那韦/利托那韦组合；添加干扰素β-1a的组合；瑞德西韦。该试验因缺乏阳性结果而中止。与此同时，人们还考虑了许多其他潜在的选择，以针对病毒本身、与宿主细胞的相互作用，或感染期间经常观察到的细胞因子风暴。其中几种选择将简要回顾。它们包括疫苗、小分子、抗体和干细胞。
